BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28986382)

  • 21. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
    Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
    Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F; Boutsalis G; Cartegni L
    PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
    Meisel Sharon S; Pozniak Y; Geiger T; Werner H
    Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
    Graff RE; Judson G; Ahearn TU; Fiorentino M; Loda M; Giovannucci EL; Mucci LA; Pettersson A
    Prostate; 2017 May; 77(6):647-653. PubMed ID: 28102015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.
    Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R
    Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
    Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
    Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
    Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
    Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ETS rearrangements and prostate cancer initiation.
    Carver BS; Tran J; Chen Z; Carracedo-Perez A; Alimonti A; Nardella C; Gopalan A; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
    Nature; 2009 Feb; 457(7231):E1; discussion E2-3. PubMed ID: 19212347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Blackburn J; Vecchiarelli S; Heyer EE; Patrick SM; Lyons RJ; Jaratlerdsiri W; van Zyl S; Bornman MSR; Mercer TR; Hayes VM
    Prostate; 2019 Jul; 79(10):1191-1196. PubMed ID: 31090091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
    Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
    J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear receptor ERRĪ± and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
    Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
    BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
    Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
    Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.
    Zhou F; Gao S; Han D; Han W; Chen S; Patalano S; Macoska JA; He HH; Cai C
    Oncogene; 2019 May; 38(22):4397-4411. PubMed ID: 30718921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A causal role for ERG in neoplastic transformation of prostate epithelium.
    Klezovitch O; Risk M; Coleman I; Lucas JM; Null M; True LD; Nelson PS; Vasioukhin V
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2105-10. PubMed ID: 18245377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.